Abstract:Craniopharyngiomas are rare malignancies of dysembryogenic origin, involving the sellar and parasellar areas. These low-grade, epithelial tumors account for two main histological patterns (adamantinomatous craniopharyngioma and papillary craniopharyngioma), which differ in epidemiology, pathogenesis, and histomorphological appearance. Adamantinomatous craniopharyngiomas typically show a bimodal age distribution (5-15 years and 45-60 years), while papillary craniopharyngiomas are limited to adult patients, especially in the fifth and sixth decades of life. Recently, craniopharyngioma histological subtypes have been demonstrated to harbor distinct biomolecular signatures. Somatic mutations in CTNNB1 gene encoding β-catenin have been exclusively detected in adamantinomatous craniopharyngiomas, which predominantly manifest as cystic lesions, while papillary craniopharyngiomas are driven by BRAF V600E mutations in up to 95% of cases and are typically solid masses. Despite the benign histological nature (grade I according to the World Health Organization classification), craniopharyngiomas may heavily affect long-term survival and quality of life, due to their growth pattern in a critical region for the presence of eloquent neurovascular structures and possible neurological sequelae following their treatment. Clinical manifestations are mostly related to the involvement of hypothalamic-pituitary axis, optic pathways, ventricular system, and major blood vessels of the circle of Willis. Symptoms and signs referable to intracranial hypertension, visual disturbance, and endocrine deficiencies should promptly raise the clinical suspicion for sellar and suprasellar pathologies, advocating further neuroimaging investigations, especially brain MRI. The optimal therapeutic management of craniopharyngiomas is still a matter of debate. Over the last decades, the surgical strategy for craniopharyngiomas, especially in younger patients, has shifted from the aggressive attempt of radical resection to a more conservative and individualized approach via a planned subtotal resection followed by adjuvant radiotherapy, aimed at preserving functional outcomes and minimizing surgery-related morbidity. Whenever gross total removal is not safely feasible, adjuvant radiotherapy (RT) and stereotactic radiosurgery (SRS) have gained an increasingly important role to manage tumor residual or recurrence. The role of intracavitary therapies, including antineoplastic drugs or sealed radioactive sources, is predominantly limited to monocystic craniopharyngiomas as secondary therapeutic option. Novel findings in genetic profiling of craniopharyngiomas have unfold new scenarios in the development of targeted therapies based on brand-new biomolecular markers, advancing the hypothesis of introducing neoadjuvant chemotherapy regimens in order to reduce tumor burden prior to resection. Indeed, the rarity of these neoplasms requires a multispecialty approach involving an expert team of endocrinologists, neurosurgeons, neuro-ophthalmologists, neuroradiologists, radiotherapists, and neuro-oncologists, in order to pursue a significant impact on postoperative outcomes and long-term prognosis.

Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma

Update on Neoadjuvant and Adjuvant BRAF Inhibitors in Papillary Craniopharyngioma: A Systematic Review

A Systematic Review of Current Targeted Therapies and Future Perspectives

Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature

Approach to the patient: New era emerges for craniopharyngioma management

BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study

Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma

Advances in the treatment of Adamantinomatous craniopharyngioma: How to balance tumor control and quality of life in the current environment: a narrative review

Advances in the management of craniopharyngioma in children and adults

Exploiting BRAF mutations in the therapeutic approach towards oral and maxillofacial tumors

Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors

Innv-19. Multimodal Therapy For Braf V600E Mutant Melanoma Brain Metastases: Characterization Of Chronological Treatment Strategies And Associations With Overall Survival

The Diagnosis and Treatment of Craniopharyngioma

Craniopharyngioma-An update on metabolic and cognitive complications and new therapy

Multimodality Therapy of Patients with Refractory Meningiomas

The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment

Craniopharyngioma in Pediatrics and Adults

Endoscopic endonasal approaches for the management of cranial base malignancies: histologically guided treatment and clinical outcomes

The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol

Csig-29. Braf Inhibitor Therapy In Braf-Mutated Primary Brain Tumors: A Single-Center Experience

The Role of Radiosurgery in the Treatment of Craniopharyngiomas